{
    "medicine_id": "c5b4964a4595e8b5f89e5a7f7b4c17fe69f2980a",
    "platform_id": "DB15874",
    "metadata": {
        "name": "Replagal 1 mg ml Injection solution concentrate",
        "composition": "1 mg ml Agalsidase alfa",
        "clinical_particulars": {
            "therapeutic_indications": "Agalsidase alfa is indicated in the treatment of Fabry disease L16398",
            "contraindications": {
                "disease": "Data regarding overdoses of agalsidase alfa are not readily available L16398 Patients experiencing an overdose of agalsidase alfa may experience an increased incidence and severity of adverse effects Overdose can be managed through the use of symptomatic and supportive measures",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Agalsidase alfa is a recombinant human \u03b1 galactosidase A used as enzyme replacement therapy in the treatment of Fabry disease L16398 It has a long duration of action and a wide therapeutic index L16398 Patients should be counselled regarding the risk of infusion related reactions and hypersensitivity L16398",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00608",
                        "description": "The therapeutic efficacy of Agalsidase alfa can be decreased when used in combination with Chloroquine"
                    },
                    {
                        "drugbank-id": "DB01118",
                        "description": "The therapeutic efficacy of Agalsidase alfa can be decreased when used in combination with Amiodarone"
                    },
                    {
                        "drugbank-id": "DB00600",
                        "description": "The therapeutic efficacy of Agalsidase alfa can be decreased when used in combination with Monobenzone"
                    },
                    {
                        "drugbank-id": "DB00798",
                        "description": "The therapeutic efficacy of Agalsidase alfa can be decreased when used in combination with Gentamicin"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}